drugset / Trial / NCT01046084

Lansoprazole 30 mg DR Capsule Replicate Food Study

NCT01046084

Phase 1 Completed 50 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under non-fasting conditions.

Timeline

Start
2003-08
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg

Indications

No indication recorded.